TEVA-TICLOPIDINE TABLET Canada - English - Health Canada

teva-ticlopidine tablet

teva canada limited - ticlopidine hydrochloride - tablet - 250mg - ticlopidine hydrochloride 250mg - platelet aggregation inhibitors

TICLOPIDINE HYDROCHLORIDE- ticlopidine hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

ticlopidine hydrochloride- ticlopidine hydrochloride tablet, film coated

eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning  and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active